The expression of CXCL13 in baseline tumor tissues, along with an ARID1A mutation in tumor cells, has been identified as a predictor of successful clinical responses in metastatic urothelial carcinoma patients treated with nivolumab, an immune checkpoint therapy, through whole-exome sequencing [199]. Here, ARID1A is linked to neoplasm.